Novartis’s Entresto Receives US FDA’s Approval for Chronic Heart Failure

 Novartis’s Entresto Receives US FDA’s Approval for Chronic Heart Failure

Novartis’s Entresto Receives US FDA’s Approval for Chronic Heart Failure

Shots:

  • The approval is based on P-III PARAGON-HF study involves assessing of Entresto (sacubitril/valsartan) in the treatment of patients with preserved ejection fraction HFpEF
  • The expanded indication enables potential treatment of adults with left ventricular ejection fraction (LVEF) below normal, benefits are most clearly evident
  • Entresto is the 1st and only therapy approved in the US to treat patients diagnosed with guideline defined heart failure to include both those with HFrEF and many with HFpEF

Click here ­to­ read full press release/ article | Ref: Novartis | Image: Penn Medicine

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post